Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Just In
When and where for a Fourth of July celebration near you! ð
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mainz Biomed N.V. - Ordinary Shares
(NQ:
MYNZ
)
0.3351
-0.0039 (-1.15%)
Streaming Delayed Price
Updated: 12:56 PM EDT, Jul 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
204,247
Open
0.3389
Bid (Size)
0.3313 (59)
Ask (Size)
0.3599 (10)
Prev. Close
0.3390
Today's Range
0.3300 - 0.3700
52wk Range
0.3150 - 5.010
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
July 02, 2024
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens...
Via
Benzinga
Exposures
COVID-19
Mainz Biomed Provides Half Year 2024 Corporate Update
July 02, 2024
Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study
From
Mainz BioMed NV
Via
GlobeNewswire
Performance
YTD
-71.36%
-71.36%
1 Month
-61.39%
-61.39%
3 Month
-68.97%
-68.97%
6 Month
-70.86%
-70.86%
1 Year
-92.86%
-92.86%
More News
Read More
Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
June 26, 2024
Via
Benzinga
Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks
June 21, 2024
Via
News Direct
Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate
June 05, 2024
Via
News Direct
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
June 04, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
June 04, 2024
Via
Benzinga
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
June 03, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Reports Results of 2024 Annual General Meeting
May 31, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
May 29, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
May 29, 2024
Via
InvestorPlace
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
May 28, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
May 20, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 17, 2024
Via
InvestorPlace
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
May 16, 2024
Via
Benzinga
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
May 07, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
mRNA Is Promising A Breakthrough In Fighting Cancer
April 29, 2024
Via
Benzinga
Exposures
COVID-19
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
April 25, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
April 10, 2024
Via
Benzinga
MYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023
April 09, 2024
Via
InvestorPlace
Mainz Biomed Reports Full Year 2023 Financial Results
April 09, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
April 02, 2024
Via
Benzinga
Exposures
COVID-19
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
March 19, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
March 18, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
March 12, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.